

Nicholas G Nickols

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3895193/publications.pdf>

Version: 2024-02-01

64
papers

3,133
citations

201385

27
h-index

161609

54
g-index

65
all docs

65
docs citations

65
times ranked

3387
citing authors

#	ARTICLE	IF	CITATIONS
1	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	3.8	252
2	⁶⁸ Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237.	2.8	226
3	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2019, 2, e188006.	2.8	221
4	Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16768-16773.	3.3	211
5	Improved nuclear localization of DNA-binding polyamides. <i>Nucleic Acids Research</i> , 2007, 35, 363-370.	6.5	208
6	Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10418-10423.	3.3	183
7	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
8	Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1α-DNA Interface. <i>ACS Chemical Biology</i> , 2007, 2, 561-571.	1.6	120
9	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	2.8	113
10	Antitumor activity of a pyrrole-imidazole polyamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1863-1868.	3.3	111
11	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	2.8	94
12	Randomized prospective phase III trial of ⁶⁸ Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>BMC Cancer</i> , 2019, 19, 18.	1.1	86
13	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	0.9	83
14	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	2.8	81
15	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	5.1	68
16	A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2207-2212.	0.4	54
17	Activity of a Pyrimidine Polyamide Targeted to the Estrogen Response Element. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 675-684.	1.9	48
18	Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. <i>JAMA Network Open</i> , 2022, 5, e2144027.	2.8	43

#	ARTICLE	IF	CITATIONS
19	The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 557-567.	2.8	41
20	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37
21	High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1505-1515.	3.2	36
22	Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. <i>Frontiers in Immunology</i> , 2018, 9, 2925.	2.2	32
23	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021, 7, 238-240.	1.6	31
24	Animal Toxicity of Hairpin Pyrrole-Imidazole Polyamides Varies with the Turn Unit. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7449-7457.	2.9	30
25	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
26	Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 539.	1.3	29
27	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. <i>BMC Cancer</i> , 2021, 21, 538.	1.1	29
28	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 268-275.	1.1	27
29	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	3.4	27
30	Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 731-737.	0.4	27
31	aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in ¹⁸ F-DCFPyL Images of Veterans with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 233-239.	2.8	25
32	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021, 154, 207-213.	0.3	24
33	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 628-636.	0.4	20
34	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. <i>Brachytherapy</i> , 2017, 16, 1106-1112.	0.2	19
35	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.3	19
36	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-level data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	0.9	18
38	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
39	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. <i>European Urology Oncology</i> , 2022, 5, 100-103.	2.6	18
40	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
41	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
42	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. <i>BMC Cancer</i> , 2019, 19, 291.	1.1	17
43	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
44	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	1.1	14
45	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 930-935.	0.4	12
46	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
47	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
48	Treatment of the primary tumor in metastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2597-2606.	1.2	11
49	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
50	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 135-139.	2.0	11
51	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-Institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.4	10
52	Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 149-154.	0.4	9
53	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. <i>Radiotherapy and Oncology</i> , 2022, 166, 1-7.	0.3	9
54	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	8

#	ARTICLE	IF	CITATIONS
55	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 207-209.	2.0	8
56	Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 404-411.	0.6	6
57	Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy. <i>European Urology Focus</i> , 2021, 7, 250-253.	1.6	6
58	The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 1364-1369.	0.6	5
59	Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. <i>PLoS ONE</i> , 2018, 13, e0196803.	1.1	4
60	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 786.	1.3	3
61	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	2.6	3
62	Optimal patient selection for stereotactic body radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e661.	5.1	2
63	Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. <i>Advances in Radiation Oncology</i> , 2021, 6, 100759.	0.6	1
64	Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. <i>Advances in Radiation Oncology</i> , 2022, 7, 100944.	0.6	1